Indraprastha Medical Corporation Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison
Indraprastha Medical Corporation Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison
Last Updated on: Oct 25, 2026
Key Highlights
The Latest Trading Price of Indraprastha Medical Corporation Ltd is ₹ 299.95 as of 23 Oct 15:30
. The P/E Ratio of Indraprastha Medical Corporation Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Indraprastha Medical Corporation Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Indraprastha Medical Corporation Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Indraprastha Medical Corporation Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Indraprastha Medical Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0%
The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57%
The Dividend Payout of Indraprastha Medical Corporation Ltd changed from 39.1 % on March 2022 to 19.97 % on March 2026 . This represents a CAGR of -12.57% over 5 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .
About Indraprastha Medical Corporation Ltd
Indraprastha Medical Corporation Limited was incorporated on 16th March, 1988.
The main business of the Company is to enhance the quality of life of patients by providing comprehensive, high-quality hospital services on a cost-effective basis.
The Company was formed as a joint venture between the Government of Delhi and the Apollo Hospitals Group to establish the Indraprastha Apollo Hospitals.
The Hospital provides international standard medical care, offering a wide range of multi-specialty services.
Key specialties with strong growth and revenue potential include transplants, cardiology, oncology, neurology, and orthopaedics.
The company came out with the public issue of 2,29,18,300 equity shares of Rs 10 each for cash at par aggregating Rs 22,91,83,000.
IMCL is setting up a multi-disciplinary super speciality teritary care referral hospital at New Delhi.
About Yatharth Hospital & Trauma Care Services Ltd
Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC.
Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care.
The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care
hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.
FAQs for the comparison of Indraprastha Medical Corporation Ltd and Yatharth Hospital & Trauma Care Services Ltd
Which company has a larger market capitalization, Indraprastha Medical Corporation Ltd or Yatharth Hospital & Trauma Care Services Ltd?
Market cap of Indraprastha Medical Corporation Ltd is 2,749 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,978 Cr
What are the key factors driving the stock performance of Indraprastha Medical Corporation Ltd and Yatharth Hospital & Trauma Care Services Ltd?
The stock performance of Indraprastha Medical Corporation Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Indraprastha Medical Corporation Ltd and Yatharth Hospital & Trauma Care Services Ltd?
As of October 25, 2026, the Indraprastha Medical Corporation Ltd stock price is INR ₹299.95. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹931.85.
How do dividend payouts of Indraprastha Medical Corporation Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?
To compare the dividend payouts of Indraprastha Medical Corporation Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.